(Total Views: 44)
Posted On: 08/23/2021 10:52:02 AM
Post# of 42884
Re: trooperstocks #28058
$GANX - Important developments for Parkinson's Disease and other serious disorders described in the latest company update. The CEO sums up nicely in his direct comments:
Eric Richman, Chief Executive Officer of Gain, added, “We are pleased with the progress in advancing our preclinical compounds to the clinic and announced important and compelling data related to our GBA Parkinson’s program. Our SEE-Tx supercomputing platform technology designed to identify novel allosteric binding sites on misfolded proteins continues to meet objectives within our internal pipeline and our external pharmaceutical partnerships. We continue to advance our pipeline towards achieving our mission in redefining drug discovery and developing novel therapies for devastating conditions with significant unmet medical need.”
NEWS LINK: https://www.globenewswire.com/news-release/2021/08/11/2279160/0/en/Gain-Therapeutics-Inc-Reports-Second-Quarter-2021-Financial-Results-and-Business-Update.html
Eric Richman, Chief Executive Officer of Gain, added, “We are pleased with the progress in advancing our preclinical compounds to the clinic and announced important and compelling data related to our GBA Parkinson’s program. Our SEE-Tx supercomputing platform technology designed to identify novel allosteric binding sites on misfolded proteins continues to meet objectives within our internal pipeline and our external pharmaceutical partnerships. We continue to advance our pipeline towards achieving our mission in redefining drug discovery and developing novel therapies for devastating conditions with significant unmet medical need.”
NEWS LINK: https://www.globenewswire.com/news-release/2021/08/11/2279160/0/en/Gain-Therapeutics-Inc-Reports-Second-Quarter-2021-Financial-Results-and-Business-Update.html
(0)
(0)Scroll down for more posts ▼
